Analysts will also be seeking clarity on any potential impact from the US government’s most favoured nation pricing norms, and on the company’s plans after getting regulatory approval to market semaglutide as a weight-loss drug in India earlier this month.
Recent Posts
- Bitcoin’s battle for $70K continues as data shows traders avoiding bullish positioning
- Stock futures are little changed after Monday’s relief rally; traders eye latest developments in Iran: Live updates
- Volume in stock and oil futures surged minutes before Trump’s market-turning post
- Chevron CEO says Iran war impact isn’t fully priced into oil market, traders have ‘scant information’
- Asia wants more U.S. oil and gas to reduce Middle East dependence after Iran war, Burgum says